Iv%25252525252525252525252525252520gentamicin

# IV Gentamicin ## Overview Gentamicin is an aminoglycoside antibiotic that exerts bactericidal activity by binding to the 30S ribosomal subunit, inhibiting protein synthesis. It provides excellent coverage against aerobic Gram-negative bacilli, including *Pseudomonas aeruginosa*. ## Primary Indications * Serious Gram-negative infections (e.g., bacteremia, pneumonia, complicated UTI). * Synergy with beta-lactams or vancomycin for Gram-positive endocarditis. * Empiric treatment of neonatal sepsis. ## Adult Dosing * **Conventional (Divided) Dosing:** 1.5–2.5 mg/kg IV every 8–12 hours. * **Extended-Interval (Once-Daily) Dosing:** 5–7 mg/kg IV every 24 hours (preferred to reduce nephrotoxicity and leverage concentration-dependent killing). * **Synergy for Endocarditis:** 1 mg/kg IV every 8 hours. * *Note: Dosing must be based on Ideal Body Weight (IBW) or Adjusted Body Weight if obese.* ## Pediatric Dosing * **Neonates (0–28 days):** 2.5–5 mg/kg per dose, frequency determined by gestational age (usually every 18–48 hours). * **Infants/Children (1 month–18 years):** 2.5 mg/kg IV every 8 hours (conventional) or 5–7.5 mg/kg IV every 24 hours (extended-interval). * *Note: Always verify local institutional neonatal/pediatric nomograms.* ## Dose Adjustments * **Renal Impairment:** Requires significant modification. Dose frequency should be extended based on serum creatinine, calculated GFR (CrCl), or by utilizing post-dose serum concentrations. * **Obesity:** Use adjusted body weight (IBW + 0.4 × [Total Body Weight - IBW]) to prevent toxicity. ## Contraindications * Hypersensitivity to aminoglycosides. * Caution in patients with myasthenia gravis (may exacerbate muscle weakness). ## Adverse Effects * **Nephrotoxicity:** Usually reversible; associated with trough levels and prolonged therapy. * **Ototoxicity:** Vestibular (vertigo, ataxia) and auditory (tinnitus, hearing loss); often irreversible. * **Neuromuscular Blockade:** Rare, but can lead to respiratory depression. ## Key Drug Interactions * **Loop Diuretics (e.g., Furosemide):** Increases risk of ototoxicity. * **Nephrotoxic Agents (e.g., Vancomycin, Amphotericin B, NSAIDs, Cyclosporine):** Increases risk of acute kidney injury. * **Neuromuscular Blocking Agents:** Potentiates blockade effects. ## Monitoring * **Therapeutic Drug Monitoring (TDM):** Essential. * **Conventional:** Monitor steady-state peaks (30 min after infusion) and troughs (just before next dose). * **Extended-Interval:** Use Hartford Nomogram or similar; measure a "random" level 6–14 hours post-dose. * **Renal Function:** Monitor serum creatinine and urine output daily. * **Auditory/Vestibular:** Monitor for hearing changes, tinnitus, or dizziness. ## Clinical Pearls * **Avoid in pregnancy:** Potential for fetal ototoxicity. * **Do not use for Monotherapy:** Not effective for respiratory tract infections due to poor penetration into pulmonary secretions and potential for local inactivation. * **Dosing Uncertainty:** Dosing is highly dependent on institutional protocols and local sensitivity patterns. Always consult your facility's pharmacy-led aminoglycoside dosing policy. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution. Always verify current prescribing information, institutional guidelines, and patient-specific factors before administering medications.